These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 34662226)
21. Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8. Mietzsch M; Barnes C; Hull JA; Chipman P; Xie J; Bhattacharya N; Sousa D; McKenna R; Gao G; Agbandje-McKenna M J Virol; 2020 Feb; 94(6):. PubMed ID: 31826994 [TBL] [Abstract][Full Text] [Related]
22. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Burger C; Gorbatyuk OS; Velardo MJ; Peden CS; Williams P; Zolotukhin S; Reier PJ; Mandel RJ; Muzyczka N Mol Ther; 2004 Aug; 10(2):302-17. PubMed ID: 15294177 [TBL] [Abstract][Full Text] [Related]
34. Adeno-associated virus (AAV) vectors in cancer gene therapy. Santiago-Ortiz JL; Schaffer DV J Control Release; 2016 Oct; 240():287-301. PubMed ID: 26796040 [TBL] [Abstract][Full Text] [Related]
35. Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction. Naumer M; Popa-Wagner R; Kleinschmidt JA J Gen Virol; 2012 Oct; 93(Pt 10):2131-2141. PubMed ID: 22764318 [TBL] [Abstract][Full Text] [Related]
36. A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. Shayakhmetov DM; Carlson CA; Stecher H; Li Q; Stamatoyannopoulos G; Lieber A J Virol; 2002 Feb; 76(3):1135-43. PubMed ID: 11773389 [TBL] [Abstract][Full Text] [Related]
37. Recent Advances in the Analysis Full/Empty Capsid Ratio and Genome Integrity of Adeno-associated Virus (AAV) Gene Delivery Vectors. Hajba L; Guttman A Curr Mol Med; 2020; 20(10):806-813. PubMed ID: 32748744 [TBL] [Abstract][Full Text] [Related]
38. Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector. Choudhury SR; Harris AF; Cabral DJ; Keeler AM; Sapp E; Ferreira JS; Gray-Edwards HL; Johnson JA; Johnson AK; Su Q; Stoica L; DiFiglia M; Aronin N; Martin DR; Gao G; Sena-Esteves M Mol Ther; 2016 Apr; 24(4):726-35. PubMed ID: 26708003 [TBL] [Abstract][Full Text] [Related]
39. Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea. Frederick A; Sullivan J; Liu L; Adamowicz M; Lukason M; Raymer J; Luo Z; Jin X; Rao KN; O'Riordan C Hum Gene Ther; 2020 Jul; 31(13-14):756-774. PubMed ID: 32578442 [TBL] [Abstract][Full Text] [Related]
40. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Bowles DE; McPhee SW; Li C; Gray SJ; Samulski JJ; Camp AS; Li J; Wang B; Monahan PE; Rabinowitz JE; Grieger JC; Govindasamy L; Agbandje-McKenna M; Xiao X; Samulski RJ Mol Ther; 2012 Feb; 20(2):443-55. PubMed ID: 22068425 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]